HRAS and thyroid gland carcinoma: The ThyroSeq v2 version was designed to detect mutations in >1,000 hotspots of 14 thyroid cancer-related genes (AKT1, BRAF, CTNNB1, GNAS, HRAS, KRAS, NRAS, PIK3CA, PTEN, RET, TP53, TSHR, TERT, and EIF1AX) and for 42 types of gene fusions or rearrangements known to occur in thyroid cancer (RET, PPARG, NTRK1, NTRK3, BRAF, and ALK), while the Afirma GEC uses a microarray measurement of mRNA of 167 genes that includes driver genes such as HRAS, NRAS, KRAS, and BRAF-V600E along with p53 and others.